GFS Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

GFS Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,500	Closed	-$518K	–	153
2022 Q1	$518K	Hold	6,500	–	–	0.11%	120
2021 Q4	$500K	Sell	6,500 -1,515	-19%	-$113K	0.08%	132
2021 Q3	$584K	Hold	8,015	–	–	0.13%	114
2021 Q2	$586K	Buy	8,015 +1,350	+20%	+$96.3K	0.13%	99
2021 Q1	$460K	Buy	+6,665	New	+$459K	0.11%	103

Other funds holding PPH

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return

Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LJAC

L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GFS Advisors's PPH Position: Q2 2022 in Review

GFS Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2022, closing a stake of 6,500 shares — an estimated $518K sold.

GFS Advisors first reported a position in PPH in Q1 2021 and held it in 5 quarters. The position peaked at $586K in Q2 2021. 91 funds tracked by Wall St. Rank hold PPH as of Q2 2022.

GFS Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q2 2022 after selling out during the quarter.
GFS Advisors sold 6,500 VanEck Pharmaceutical ETF shares in Q2 2022, an estimated $518K.
GFS Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2021 and held it in 5 quarters.
GFS Advisors's VanEck Pharmaceutical ETF position peaked at $586K in Q2 2021.
91 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2022.

Based on GFS Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.